Compare American Well Corp (AMWL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Merck & Co., Inc. — how do they compare? American Well Corp trades at $9.89 (market cap $165.58M), while Merck & Co., Inc. trades at $123.56 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 1842.7× American Well Corp's market cap, and Merck & Co., Inc. pays a 2.75% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | MRK | |
|---|---|---|
Market Cap | $165.58M | $305.12B |
Sector | Health | Health |
52-Week High | $9.91 | $129.52 |
52-Week Low | $3.78 | $77.60 |
Enterprise Value | -$9.66M | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $9.91, up 8.66% today, with bullish technical signals and positive momentum. The company shows improving financial trends with declining losses and strong gross margins of 52.9%, though it remains unprofitable with a -37.02% net margin. Recent news highlights Amazon's appointment of Amwell's co-founder to lead its healthcare unit, signaling industry validation.
While AMWL shows operational improvement and attractive valuation multiples (P/S 0.68, P/B 0.73), the stock faces headwinds from persistent losses and negative cash flow. Analyst consensus is cautious with a $7.25 price target below current levels, suggesting limited near-term upside despite recent positive momentum.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, including Q1 2026, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid a competitive pharmaceutical landscape.
The stock presents a favorable risk-reward profile with upside potential driven by earnings momentum and strategic acquisitions, though risks include patent expirations and regulatory pressures. Institutional buying activity and a 67.57% buy rating from analysts underscore confidence, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
